BioCentury | Jan 28, 2020
Clinical News

Acceleron readout supports sotatercept as disease-modifying option for PAH

...an ACVR2A antagonist that acts as a ligand trap for TGFβ superfamily members to modulate BMPRII...
...via its acquisition of Celgene Corp. Targets: ACVR2A - activin receptor type 2A; BMPRII - Bone morphogenetic protein receptor type II...
...Phosphodiesterase-5; sGC - Soluble guanylate cyclase Sandi Wong, Assistant Editor Acceleron Pharma Inc. Activin receptor type 2B (ACVR2B) Bone morphogenetic protein receptor type II (BMPRII) pulmonary...
BioCentury | Feb 6, 2019
Distillery Therapeutics

Neurology

...agonist of BMPRI and BMPRII, for bone fractures. Ember Therapeutics Inc. has Opgenra (BMP-7), a BMPRII...
...Kristi A. Wharton, Brown University, Providence, R.I. email: Kristi_Wharton@brown.edu Claire Quang Brown University Bone morphogenetic protein 7 (BMP7) (OP-1) Bone morphogenetic protein receptor type II (BMPRII) Superoxide...
BioCentury | Jan 13, 2017
Company News

Selten, Vivus deal

...receive an undisclosed upfront payment and is eligible for milestones and tiered royalties. Tacrolimus, a bone morphogenetic protein receptor type II (BMPRII)...
...has Orphan Drug designation in the U.S. to treat PAH. Ascomycin, an undisclosed compound targeting BMPRII...
BioCentury | Aug 10, 2015
Emerging Company Profile

New tac for modifying PAH

...Inc. is developing a new formulation of the generic immunosuppressive drug tacrolimus that activates the BMPRII...
...disease symptoms. No approved therapies treat the underlying inflammatory and fibrotic elements of the disease. Bone morphogenetic protein receptor type II (BMPRII)...
...It also inhibits pulmonary arterial proliferation, preventing arteries from being closed off. The discovery that BMPRII...
BioCentury | Jul 9, 2015
Distillery Therapeutics

Therapeutics: Bone morphogenetic protein 9 (BMP9; GDF2); bone morphogenetic protein receptor type II (BMPRII)

...culture and mouse studies suggest BMP9 could help treat pulmonary arterial hypertension (PAH). Mutations in BMPRII...
...have been associated with PAH pathogenesis. In assays in endothelial cells from PAH patients harboring BMPRII...
...with no pretreatment. In three mouse models of PAH, including transgenic mice expressing mutant human BMPRII...
BioCentury | Jul 14, 2011
Targets & Mechanisms

NOGO could go far

...as idiopathic PAH, familial PAH associated with mutations in bone morphogenic protein receptor type II (BMPRII...
...findings also might apply to other types of the disease. For instance, viral infections and BMPRII...
Items per page:
1 - 6 of 6